Webinar: I survived tuberculosis
We are happy to launch our webinar series featuring inspiring speakers and highlights from the key campaigns we work on. These webinars are open to everyone interested in learning more about our work and how to become a skilled advocate.
To kick us off with the first webinar, we are excited to invite you to join us for a discussion with Ingrid Schoeman a tuberculosis (TB) survivor (see bio below). During this session, we will explore what TB is, the importance of fighting this infectious disease and hear a TB survivor’s powerful experience first-hand. This talk is also perfectly timed ahead of World TB Day (March 24) that is commemorated globally and the upcoming High-Level Meeting on TB at the United Nations on September 26 2018.
You don’t want to miss this great opportunity!
Register here: http://bit.ly/TBregister
Ingrid Schoeman is a survivor of drug resistant tuberculosis and is now a powerful advocate for improving outcomes for TB patients. She is based in South Africa, where she works for a TB advocacy organization, TB Proof. She is hugely passionate, particularly when it comes to pushing for a person-centered perspective in TB prevention and care. She currently sits on the Affected Communities and Civil Society Advisory Panel, directly advocating on behalf of patients and the TB community to ensure a successful High-Level Meeting on Tuberculosis in September, 2018.
About the webinar
This webinar (Thursday March 15 at 12pm ET) will be in English. Questions in French are welcome. We expect the webinar to be about 45 minutes.
Please join the webinar by:
- connecting online: https://zoom.us/j/4339412427
- phone (audio only): +1 877 853 5257 (Toll Free)
- phone (international – audio only): https://zoom.us/zoomconference?m=KN4xS57bvtwMqrEIqmUP3zNgq6WJYL9c
- Meeting ID: 433 941 2427
Try to join a couple of minutes before the starting time. This webinar will be recorded – if you are unable to join the event but are keen to listen to the recording, please ensure to email us.
Contact us at [email protected] for any questions.